Don Bandari, MD
Cardiovascular Disease · Brooklyn, NYNPI 1558362673
Payments from drug & device makers
Across 215 payments — averaging $447.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$92K
- E.r. Squibb & Sons, L.L.C.$826
- Boehringer Ingelheim$481
- Novo Nordisk$458
- GSK$429
- AstraZeneca$208
- plus $2K from 23 others
What the payments were for
- Food & beverage$3,8644%
- Education$34,69236%
- Other$57,60060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 21 | $92,251 |
| E.r. Squibb & Sons, L.L.C. | 42 | $826 |
| Boehringer Ingelheim | 23 | $481 |
| Novo Nordisk | 23 | $458 |
| GSK | 22 | $429 |
| AstraZeneca | 11 | $208 |
| Amgen | 9 | $176 |
| Novartis | 9 | $176 |
| Medtronic(2 entities) | 3 | $133 |
| Actelion Pharmaceuticals US, Inc. | 6 | $120 |
| Pfizer | 6 | $106 |
| Amarin Pharma, Inc. | 5 | $94 |
| Merck | 4 | $82 |
| Astellas Pharma US Inc | 4 | $74 |
| Lilly USA, LLC | 4 | $72 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $59 |
| Bardy Diagnostics, Inc. | 2 | $56 |
| Abiomed | 2 | $55 |
| Arbor Pharmaceuticals, Inc. | 3 | $50 |
| Boston Scientific | 2 | $48 |
| Bayer | 2 | $43 |
| AbbVie(2 entities) | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Abbott | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaCure 1470 Pro$72,000
- EVLT$20,227
- ELIQUIS$123
- Avalus$103
How this compares
$96,156 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 508 | $463,223 |
| FarxigaDapagliflozin Propanediol | 240 | $210,351 |
| JardianceEmpagliflozin | 196 | $202,861 |
| EntrestoSacubitril/Valsartan | 190 | $200,443 |
| CamzyosMavacamten | 20 | $173,719 |
| MounjaroTirzepatide | 101 | $127,959 |
| LinzessLinaclotide | 149 | $121,239 |
| JanumetSitagliptin Phos/Metformin Hcl | 114 | $117,039 |
| XareltoRivaroxaban | 103 | $110,152 |
| OzempicSemaglutide | 99 | $102,694 |
| JanuviaSitagliptin Phosphate | 117 | $99,011 |
| TrulicityDulaglutide | 73 | $81,216 |
| Diclofenac Potassium | 14 | $62,039 |
| Repatha SureclickEvolocumab | 92 | $60,687 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 82 | $58,396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $106 | $463,223508 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere | $208 | $283,330351 claims |
| MerckJanumet, Januvia | $82 | $216,050231 claims |
| Lilly USA, LLCMounjaro, Trulicity | $72 | $209,175174 claims |
| Boehringer IngelheimJardiance | $481 | $202,861196 claims |
| NovartisEntresto | $176 | $200,443190 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $826 | $173,71920 claims |
| Novo NordiskOzempic, Rybelsus | $458 | $140,478117 claims |
| AbbVieLinzess | $30 | $121,239149 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $429 | $86,237142 claims |
| Astellas Pharma US IncMyrbetriq | $74 | $21,79735 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $50 | $17,94143 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Brooklyn
- Ronald WhartonBrooklyn$1.1M
- Ozgen DoganBrooklyn$404K
- Warren WexelmanBrooklyn$396K
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.